Last updated: February 19, 2026

What are the current market drivers and competitive forces?

The ATC class A encompasses drugs targeting the alimentary tract and metabolism disorders. Key segments include anti-diabetic agents, gastrointestinal drugs, lipid-lowering therapies, and appetite suppressants. The market's value was estimated at USD 70 billion in 2022, with a projected compound annual growth rate (CAGR) of 5.5% through 2030. Growth drivers include rising prevalence of diabetes, obesity, and gastrointestinal diseases, along with increased healthcare spending globally.

Major players such as Novo Nordisk, Eli Lilly, and Pfizer dominate, leveraging patent protection for leading products. Biologics and novel small molecules account for significant R&D investments, with a focus on precision medicine and combination therapies. Market competition is intense, with patent expiry cycles prompting aggressive licensing and M&A strategies. Biosimilars for insulin and GLP-1 receptor agonists have entered markets post-expiration, exerting pricing pressure.

What are recent trends in patent filings and expirations in this class?

Patent activity is concentrated around new molecular entities (NMEs) for diabetes, obesity, and gastrointestinal conditions. Patent filings peaked between 2012 and 2018, coinciding with the approval of key drugs like semaglutide and dulaglutide. The landscape reflects a shift toward biologics, with 58% of patents filed between 2015 and 2021 covering biologic formulations.

Major patent expirations have occurred for older drugs such as metformin (expiring in 2030 in the US and Europe) and some first-generation DPP-4 inhibitors. Patent expirations have triggered the emergence of biosimilar versions, particularly for insulin analogs, with several approved in the US and EU since 2018.

Patent filings are decentralized, involving large pharmaceutical firms, biotech startups, and universities. US leads in filings, followed by Europe and Japan. Patent protection durations typically span 10-15 years, with some extensions granted through data exclusivity periods.

How does innovation in this category influence patent strategies?

Innovation centers around improved efficacy, safety, and delivery methods. The rise of orally active biologics, dual-action molecules, and smart delivery systems features prominently in recent patents. Companies adopt encompassing patent strategies, including composition of matter, method of use, and formulation patents, to extend market exclusivity.

Collaborations between biotech firms and academia are common, advancing novel targets such as incretin pathways, nutrient sensors, and microbiome modulation. Patent filings increasingly emphasize combination therapies and personalized treatment methods, creating patent thickets that hinder generic entry.

What is the legal landscape for patent enforcement and challenges?

Patent litigation is common in ATC class A, especially concerning biosimilars and biologics. Courts focus on issues like patent obviousness, novelty, and infringement. Patent linkage regulations in the US and EU facilitate market entry of biosimilars post-patent expiry, but patent thickets prolong exclusivity.

Patent opposition procedures in Europe and patent invalidation requests in the US challenge weak patents, especially those covering incremental innovations. Patent term extensions depend on patent prosecution delays and regulatory review periods, typically securing an additional 5-7 years of exclusivity.

Key patent-related policies influencing the market

Patent linkage laws aim to prevent biosimilar market entry before patent expiry.
Data exclusivity periods shield innovator data from use by generics for 5-12 years.
Patent term extensions can lengthen effective protection, particularly in regulatory approval phases.
Compulsory licensing remains limited for these drugs but can influence patent valuation and enforcement strategies.

Patent landscape overview: key patents and companies

Company	Key Patents	Focus Area
Novo Nordisk	Insulin formulations, GLP-1 analogs	Diabetes, obesity
Eli Lilly	Tirzepatide, oral GLP-1 receptor agonists	Diabetes, metabolic syndrome
Pfizer	Lipid-lowering agents, combination therapies	Hyperlipidemia, gastrointestinal diseases
BioNTech, Moderna	mRNA-based metabolic therapies	Emerging gene and immune therapies

The patent landscape features a mix of composition patents, method-of-use applications, and formulation patents. Large patent families cover blockbuster drugs such as Ozempic (semaglutide) and Trulicity (dulaglutide).

Conclusions

Market dynamics are shaped by the rising prevalence of metabolic and gastrointestinal diseases, continuous innovation in biologics and rare disease therapies, and patent expiration cycles. Patent strategies emphasize broad coverage, including process innovations, combination patents, and use claims. Challenges include patent cliffs and biosimilar competition, countered by active patent litigation and licensing.

Key Takeaways

Dominant drugs: GLP-1 receptor agonists, insulin analogs, lipid-lowering agents.
Innovation focus: biologics, oral biologics, delivery methods.
Patent expirations: starting around 2028, opening biosimilar markets.
Litigation: frequent, especially around biosimilars and incremental patents.
Regulatory protection: combined with patent law to extend market exclusivity.

FAQs

When do key patents for current blockbusters expire? Patents for drugs like semaglutide are expected to expire around 2030-2032, with some extensions possible.
What emerging technologies are patenting innovation in metabolism treatments? Oral biologics, microbiome-based therapies, and combination therapies are prominent in recent patents.
How does biosimilar entry impact the market? Biosimilars exert downward pressure on prices and market shares post-patent expiry, encouraging innovation in new formulations.
Are patent challenges common in this sector? Yes, especially concerning biologic patents and biosimilar approvals, with legal disputes frequently occurring.
What regulatory policies influence patent strategies? Patent linkage laws, data exclusivity periods, and patent term extensions heavily shape patent planning and enforcement.

References

[1] European Medicines Agency. (2022). Innovator and biosimilar medicines. Retrieved from https://www.ema.europa.eu/en/human-regulatory/overview/innovator-biosimilar-medicines

Drugs in ATC Class A

Subclasses in ATC: A - Alimentary tract and metabolism

Market dynamics and patent landscape for ATC Class A: Alimentary tract and metabolism